Stifel sees AtkinsRealis outperforming peers despite potential near-term headwinds

Stifel says AtkinsRealis trades at a premium 2027 P/E of 18.5x versus Stantec at 16.9x and WSP Global at 15.4x, while its Q1 2026 adjusted EBITDA estimate of $225 million is 6% below the $238 million consensus. The firm's full-year 2026 EBITDA view of $1.184 billion is in line with expectations. Stifel sees temporary Nuclear backlog weakness until new awards arrive in 2H 2026, but said it would consider buying on weakness given the business outlook and underleveraged balance sheet.

Analysis

The key message is not that AtkinsRealis is expensive, but that the market is paying up for a financing- and execution-sensitive Nuclear optionality story while the near-term tape is likely to be driven by backlog timing, not earnings power. When a stock already trades above peers on forward multiples, any pause in contract conversion tends to compress the multiple faster than the underlying estimate changes, because investors lose confidence in the growth-duration narrative before they revise outer-year numbers.

That creates a second-order opportunity across the peer set: if one participant is being rewarded for a cleaner Nuclear catalyst path, the rest of the engineering/infrastructure complex can get de-rated simply because capital rotates toward the “highest quality” compounder in the basket. Stantec and WSP may therefore face pressure not only from their own fundamentals but from relative-value outflows if investors decide the group deserves a lower blended multiple while waiting for Nuclear awards to re-accelerate.

The timing matters. The weakness window is likely to last through the next 1-2 quarters because the market will focus on whether early-2026 EBITDA misses are a one-off or evidence of a slower project ramp. If contract awards materialize in the second half of 2026, the setup can flip quickly: the balance sheet gives management room to defend growth through a lull, which means the stock could re-rate sharply once backlog visibility improves and the market starts discounting 2027-2028 cash flows again.

Contrarian view: the premium may be justified if investors are underestimating how scarce large-scale Nuclear exposure is in public markets. In that case, every pullback becomes a liquidity event rather than a thesis break, and the right question is not whether the stock is cheap, but whether competitors can actually grow fast enough to deserve their own multiples. The market may be over-focusing on one quarter’s EBITDA variance and underpricing the embedded option value of a capital-light balance sheet in a business with long-dated contract wins.

Key Decisions for Investors

• Buy AtkinsRealis on a 5-8% pullback over the next 1-3 months; use weakness to build a starter position, targeting a re-rating into H2 2026 contract wins. Risk/reward: near-term downside from backlog noise, but 15-20% upside if Nuclear awards restore growth visibility.
• Pair trade: long ATRL / short WSP.TO for 3-6 months. The relative thesis is that ATRL retains the Nuclear option premium while WSP is more exposed to multiple compression if infrastructure investors de-risk the group. Tighten if the spread widens materially before contract catalysts.
• For investors already long the engineering group, rotate a portion from WSP.TO into STN or cash until backlog commentary improves. This is a lower-beta way to express caution on relative valuation without making a full sector short.
• If available, buy 6-9 month call spreads on ATRL rather than outright stock on strength. That captures the potential H2 2026 catalyst while limiting theta bleed if the market continues to punish near-term backlog uncertainty.
• Set a catalyst watch for new Nuclear awards in H2 2026; if awards land and backlog inflects, add aggressively on the first post-announcement consolidation, as the market is likely to reprice the long-duration earnings stream quickly.